Clinical heterogeneity of pediatric hepatocellular carcinoma
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Apr 2020 · 1 min read
In brief
In brief
Retrospective study of 32 pediatric HCC patients reveals significant clinical heterogeneity, with 53% having genetic/anatomic predispositions and two distinct histologic subtypes. Surgical resection was the primary determinant of survival (66% vs 22% with medical therapy alone), with liver transplantation enabling cure in select stage 3 patients.
Written by the GCMD Library team from the article.
Statements in this article
Hepatocellular carcinoma is often a chemoresistant neoplasm with a poor prognosis.
The median age of pediatric hepatocellular carcinoma patients in this series was 11.5 years with a range of 1-20 years.
Seventeen of 32 patients (53%) had a genetic or anatomic predisposition to hepatocellular carcinoma.
Histology was conventional HCC in 25 patients and fibrolamellar HCC in 7 patients.
Evans staging distribution was stage 1 in 12 patients, stage 2 in 1 patient, stage 3 in 10 patients, and stage 4 in 9 patients.
Sixteen patients underwent resection at diagnosis and five patients underwent resection after neoadjuvant chemotherapy.
Surgical procedures included liver transplantation in 11 patients, hemihepatectomy in 9 patients, and segmentectomy in 1 patient.
Eighteen patients received medical therapy, with 13 receiving neoadjuvant therapy and 5 receiving adjuvant therapy.
The most common initial medical therapies were sorafenib alone in 7 patients and cisplatin/doxorubicin-based therapy in 8 patients.
Overall survival was 43.8% (14 of 32 patients) with a median follow-up of 58.8 months (range 26.5-157.6 months).
Cause of death was most often linked to lack of primary tumor surgery in 11 patients.
Among survivors, Evans stage distribution was stage 1 in 11 patients, stage 2 in 1 patient, and stage 3 in 2 patients (both treated with liver transplantation).
Four of 18 patients (22%) who received medical therapy survived.
Eight of 17 patients (47%) with a genetic or anatomic predisposition survived.
Fourteen of 21 patients (66%) who underwent surgery survived.